Endo announces licensing agreement for Paladin Labs to commercialise abaloparatide in Canada

4824

Endo International announced in a press release that its subsidiary Endo Ventures has entered into definitive agreements with Radius Health to register, commercialise and distribute abaloparatide on an exclusive basis in Canada.

According to the company, abaloparatide is a parathyroid hormone-related protein (PTHrP) analog under investigation for osteoporosis; it is not approved in Canada.  Abaloparatide is an anabolic (bone-forming) agent self-administered once daily. Paladin plans to file a New Drug Submission (NDS) with Health Canada for abaloparatide-SC by the first quarter of 2022.

Paladin Labs, an operating company of Endo, will be responsible for all commercial activities related to abaloparatide. Under the agreement, Endo obtained the rights to abaloparatide-subcutaneous injection (abaloparatide-SC) and abaloparatide-transdermal patch (abaloparatide-TD), a novel formulation and route of administration currently undergoing clinical development.

In accordance with the terms of the agreements, if abaloparatide is approved in Canada, Paladin will be responsible for the registration, distribution, sales, marketing, medical affairs, pricing and reimbursement activities in connection with commercialisation while Radius will be responsible for supplying the drug to Paladin.

“We are very pleased to work with Radius to possibly bring a new treatment option to the market for Canadian osteoporosis patients,” said Livio Di Francesco, vice president and general manager of Paladin (Montreal, Canada). “This transaction marks our entry into the endocrine and metabolic therapeutic space.  Abaloparatide has shown promising clinical evidence to address an unmet need and it has the potential to become a very important addition to our existing Canadian portfolio.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here